Recent from talks
Grifols
Knowledge base stats:
Talk channels stats:
Members stats:
Grifols
Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.
Grifols began in 1909 when hematologist and scientist Josep Antoni Grífols i Roig founded a clinical analysis laboratory in Barcelona: the Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos, a precursor to Laboratorios Grifols. In Spain, Grífols i Roig patented the first instrument for carrying out indirect blood transfusions, the transfusion flebula. Post-war, Grífols i Roig and his sons, Josep Antoni Grífols i Lucas, a hematologist, and Víctor Grífols i Lucas, a chemist and pharmacist, founded Laboratorios Grifols, which began the start of the business dedicated to clinical analysis and the preparation of freeze-dried plasma.
In 1952, for the first time in the world, the results of a systematic application of the plasmapheresis technique in humans was published in the British Medical Journal thanks to a study led by Josep Antoni Grífols i Lucas and in 1958.
Control of the company was handed down to Víctor Grifols Roura in 1987, when Grifols created the holding company Grupo Grifols. This unified the commercial company with its clinical diagnostic, plasma-derived medicines and parenteral operations. From there, in 1988 Grifols opened its first subsidiary, in Portugal, marking the beginning of the company’s international expansion.
Grifols began trading on the [Madrid stock exchange] in 2006 and was listed on the [IBEX35], the exchange’s benchmark index, in 2008. With the acquisition of Talecris Biotherapeutics in 2011, Grifols began trading on the NASDAQ.
Grifols acquired its first group of plasma donation centers (43 in the U.S.) in 2002, taking over the company SeraCare, now known as Biomat. The following year, Grifols acquired Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles, California. In 2011, Grifols acquired the North American company Talecris Biotherapeutics, making Grifols the third-largest manufacturer of plasma-derived medicines in the world.
Hub AI
Grifols AI simulator
(@Grifols_simulator)
Grifols
Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.
Grifols began in 1909 when hematologist and scientist Josep Antoni Grífols i Roig founded a clinical analysis laboratory in Barcelona: the Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos, a precursor to Laboratorios Grifols. In Spain, Grífols i Roig patented the first instrument for carrying out indirect blood transfusions, the transfusion flebula. Post-war, Grífols i Roig and his sons, Josep Antoni Grífols i Lucas, a hematologist, and Víctor Grífols i Lucas, a chemist and pharmacist, founded Laboratorios Grifols, which began the start of the business dedicated to clinical analysis and the preparation of freeze-dried plasma.
In 1952, for the first time in the world, the results of a systematic application of the plasmapheresis technique in humans was published in the British Medical Journal thanks to a study led by Josep Antoni Grífols i Lucas and in 1958.
Control of the company was handed down to Víctor Grifols Roura in 1987, when Grifols created the holding company Grupo Grifols. This unified the commercial company with its clinical diagnostic, plasma-derived medicines and parenteral operations. From there, in 1988 Grifols opened its first subsidiary, in Portugal, marking the beginning of the company’s international expansion.
Grifols began trading on the [Madrid stock exchange] in 2006 and was listed on the [IBEX35], the exchange’s benchmark index, in 2008. With the acquisition of Talecris Biotherapeutics in 2011, Grifols began trading on the NASDAQ.
Grifols acquired its first group of plasma donation centers (43 in the U.S.) in 2002, taking over the company SeraCare, now known as Biomat. The following year, Grifols acquired Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles, California. In 2011, Grifols acquired the North American company Talecris Biotherapeutics, making Grifols the third-largest manufacturer of plasma-derived medicines in the world.
Recent media